Market Overview

Benzinga's Top Initiations

Related ACAD
ACADIA Pharmaceuticals Announces Stephen Davis As Executive VP, CFO And Chief Business Officer
4 Biotech Stocks Worth A Look Ahead Of FDA Approvals

Analysts at Deutsche Bank initiated coverage on shares of Sarepta Therapeutics (NASDAQ: SRPT) with a “buy” rating. The target price range for Sarepta Therapeutics is set to $45. Sarepta Therapeutics' shares closed at $33.03 yesterday.

Jefferies initiated coverage on shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) with a “buy” rating. The target price for ACADIA Pharmaceuticals is set to $13. ACADIA Pharmaceuticals' stock closed at $6.18 yesterday.

Topeka Capital initiated coverage on shares of Schnitzer Steel Industries (NASDAQ: SCHN) with a “hold” rating. The target price for Schnitzer Steel Industries is set to $27. Schnitzer Steel Industries' shares closed at $28.60 yesterday.

Analysts at Bank of America initiated coverage on shares of Pluristem Therapeutics (NASDAQ: PSTI) with a “hold” rating. The target price for Pluristem Therapeutics is set to $3.50. Pluristem Therapeutics' shares closed at $3.17 yesterday.

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Most Popular

Related Articles (ACAD + PSTI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional